Hormone receptor-positive breast cancer and black race: does sex matter?
Open Access
- 12 August 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 190 (1) , 111-119
Abstract
Purpose Black breast cancer patients have worse clinical outcomes than their White counterparts. There are few studies comparing clinical outcomes between Black male breast cancer (MBC) and female breast cancer (FBC) patients. The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC. Methods The National Cancer Database was queried for all Black MBC and FBC patients, ages 18–90, with hormone receptor-positive breast cancer diagnosed between 2010 and 2016. Hormone receptor positivity was defined as estrogen receptor-positive, progesterone-positive and HER 2-negative cancer. Sociodemographic and clinical variables were compared between MBC and FBC patients on bivariable analysis. After propensity score matching, overall survival was evaluated using the log-rank test and Cox proportional hazards. Results Compared to FBC patients, MBC patients had higher rates of metastatic disease (stage 4, MBC 4.4% vs. FBC 2.6%, p < 0.001), larger tumors (tumor size < 2 cm, MBC 32.1 vs. FBC 49.1%, p < 0.001) and a higher percentage of poorly differentiated tumors (grade 3, MBC 28.5% vs. FBC 21.4%, p < 0.001). MBC patients had lower rates of hormone therapy (MBC 66.4% vs. FBC 80.7%, p < 0.001) and neoadjuvant chemotherapy (MBC 5.8% vs. FBC 7.5%, p = 0.05) than FBC. On propensity score matched analysis, Black MBC patients had a higher overall mortality (p25 of 60 months vs. 74 months) compared to FBC patients (p = 0.0260). Conclusion Among hormone receptor-positive Black MBC and FBC patients, there are sex-based disparities in stage, hormone therapy use and overall survival.Keywords
Funding Information
- National Institutes of Health (K12 CA133250)
This publication has 33 references indexed in Scilit:
- A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for changeCA: A Cancer Journal for Clinicians, 2015
- Breast Cancer DisparitiesSurgical Oncology Clinics of North America, 2014
- Gender Differences in Breast Cancer: Analysis of 13,000 Breast Cancers in Men from the National Cancer Data BaseAnnals of Surgical Oncology, 2012
- Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy TrialJNCI: Journal of the National Cancer Institute, 2012
- Incidence and Outcome of Male Breast Cancer: An International Population-Based StudyJournal of Clinical Oncology, 2011
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer PatientsJournal of Clinical Oncology, 2010
- Male Breast Cancer: A Population-Based Comparison With Female Breast CancerJournal of Clinical Oncology, 2010
- Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology GroupJNCI: Journal of the National Cancer Institute, 2009
- Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2008
- The role of racial identity in perceived racial discrimination.Journal of Personality and Social Psychology, 2003